AIDS Vaccine Advocacy Coalition

The AIDS Vaccine Advocacy Coalition, commonly known as AVAC, is an international nonprofit organization headquartered in New York City that works to accelerate the ethical development and delivery of HIV prevention technologies. Founded in 1995, the organization emerged in response to the need for a stronger public-interest voice in AIDS vaccine research and has broadened its work to cover a wider range of HIV prevention options, including vaccines, microbicides, and other biomedical technologies. AVAC combines public education, policy analysis, advocacy, and community mobilization. Its role is not primarily to manufacture or sell medical products. Instead, it seeks to influence the research, financing, regulation, introduction, and equitable distribution of interventions intended to prevent HIV. The organization emphasizes the participation of communities affected by HIV and AIDS, arguing that research and public-health decisions should reflect the needs and rights of populations who may eventually use or receive new technologies. A central part of AVAC’s work is independent analysis of AIDS vaccine research and development. Through public-interest advocacy, the organization seeks to maintain political and financial support for research while also pressing researchers, governments, funders, and implementers to address ethical standards, informed participation, access, and affordability. Its remit includes helping communities understand developments in HIV prevention science and supporting community engagement in clinical research and policy discussions. Although the organization began with a specific focus on AIDS vaccines, its stated mission has expanded alongside the HIV prevention field. AVAC addresses the ethical introduction and distribution of life-saving technologies and works across the boundaries of scientific research, public policy, and community organizing. This positioning allows it to act as an intermediary between affected communities, scientific institutions, civil-society organizations, public agencies, and philanthropic or international health funders. Publicly identified supporters and partners have included the Bill & Melinda Gates Foundation, Ford Foundation, International AIDS Vaccine Initiative, Until There’s a Cure Foundation, Broadway Cares/Equity Fights AIDS, Gill Foundation, Overbrook Foundation, USAID, Children’s Investment Fund Foundation, Combined Federal Campaign, FHI 360, UNAIDS, and the MAC AIDS Fund. The presence of these funders reflects the organization’s dependence on philanthropic, governmental, and international-health support rather than commercial product revenue. AVAC’s work has an international orientation, even though its headquarters are in the United States. Its community-based approach is intended to support populations across regions affected by HIV and to promote ethical access to new prevention tools when they become available. In 2023, AVAC’s country director in Malawi, Ulanda Mtamba, was recognized as one of the BBC’s 100 Women, highlighting the organization’s role in HIV advocacy and community engagement in Malawi. AVAC remains an active nonprofit advocacy organization focused on HIV prevention research, policy, and equitable implementation.

AVAC was founded in 1995 as a community- and consumer-based organization responding to the need for stronger advocacy in AIDS vaccine research and development. From the beginning, its purpose was to ensure that research into HIV vaccines was accompanied by public accountability, meaningful community participation, and attention to the ethical obligations owed to people who might participate in trials or eventually use successful products. The organization developed an advocacy model combining public education, policy analysis, and community mobilization. Rather than operating as a pharmaceutical developer, AVAC positioned itself as an independent civil-society voice able to interpret scientific and policy developments for wider audiences and to press institutions responsible for research, funding, regulation, and implementation. Its work has focused on accelerating a responsible response to the HIV epidemic while maintaining attention to informed participation, fairness, access, and distribution. As the HIV prevention field expanded beyond vaccine research, AVAC’s scope also broadened. The organization came to address other HIV prevention options, including microbicides and related biomedical technologies. This evolution reflected the practical relationship between vaccine advocacy and the wider prevention pipeline: communities and policymakers need both scientific progress and systems capable of introducing effective interventions ethically and equitably. AVAC’s approach places affected populations near the center of research and policy discussions. Its community-mobilization work is intended to help people understand clinical research and prevention technologies, contribute to decisions about research priorities, and advocate for access once safe and effective interventions are available. The organization also conducts or disseminates independent policy analysis to support public debate about AIDS vaccine research and development. The organization has been supported by a mixture of philanthropic foundations, governmental programs, international health institutions, and HIV-focused organizations. Listed funders and supporters have included the Bill & Melinda Gates Foundation, Ford Foundation, International AIDS Vaccine Initiative, Until There’s a Cure Foundation, Broadway Cares/Equity Fights AIDS, Gill Foundation, Overbrook Foundation, USAID, the Children’s Investment Fund Foundation, the Combined Federal Campaign, FHI 360, UNAIDS, and the MAC AIDS Fund. These relationships have enabled AVAC to sustain advocacy, education, and mobilization work while remaining distinct from commercial vaccine manufacturers. AVAC’s activities have an international reach, with work involving communities and institutions in countries affected by HIV. Its presence in Malawi is reflected in the identification of Ulanda Mtamba as country director there. In 2023, Mtamba was included in the BBC’s 100 Women recognition, an event that publicly underscored the contribution of HIV advocates working at country level. AVAC’s continuing role is to support ethical research, informed community participation, evidence-based policy, and equitable delivery of HIV prevention options around the world.

1. 2023Ulanda Mtamba recognized by BBC 100 Women

   AVAC’s country director in Malawi, Ulanda Mtamba, is recognized as one of the BBC 100 Women.

   Source
2. 1995AVAC is founded

   The AIDS Vaccine Advocacy Coalition is established as a community- and consumer-based nonprofit focused on accelerating ethical AIDS vaccine research and development.

   Source

An independent, community-centered public-interest advocate connecting HIV-affected communities with researchers, policymakers, funders, and implementers to promote ethical research and equitable access to prevention technologies.

• HIV vaccine advocacyAdvocacy and policy analysis1995

  AVAC’s original and continuing area of work is public-interest advocacy for the ethical development of AIDS vaccines. This includes independent analysis of research and development, public education about the vaccine pipeline, and engagement with policymakers, funders, researchers, and affected communities. The work supports scientific progress while emphasizing ethical research conduct, meaningful participation, and eventual equitable access rather than commercial product sales.

• HIV prevention advocacyPublic-health advocacy

  As the HIV prevention field broadened, AVAC extended its advocacy to prevention options beyond vaccines, including microbicides and other biomedical technologies. The organization addresses how such tools are researched, introduced, and distributed, with particular attention to communities affected by HIV and to the policy and financing conditions needed for responsible implementation.

• Community mobilization and public educationCommunity engagement1995

  AVAC uses community mobilization and public education to help affected populations participate in discussions about HIV research and prevention. These activities are intended to improve understanding of clinical research and emerging technologies, strengthen community representation, and encourage decision-making that takes account of rights, ethics, access, and local needs.

• 2023AVAC Malawi country director Ulanda Mtamba named among BBC 100 Women

  Ulanda Mtamba, identified as AVAC’s country director in Malawi, was recognized by the BBC in its 100 Women feature, bringing attention to her HIV advocacy and community-engagement work.

  Other
  Source

1. AIDS Vaccine Advocacy Coalition